Skip to main content

sigvotatug vedotin

sigvotatug vedotin: 3 clinical trials tracked.

sigvotatug vedotin evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about sigvotatug vedotin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (3)

An Open-label, Phase 1 Study to Investigate the Safety and Pharmacokinetics of SGN-B6A in Chinese Subjects With Advanced Solid Tumors

NCT06549816Registry updated 2025-12-15·Phase 1
Completed

Primary endpoint: Number of participants with adverse events (AEs)

Interventionalopen6 enrolledStarted 2024-08Completion 2025-113 sites · ChinaSeagen, a wholly owned subsidiary of Pfizer

A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)

NCT06012435Registry updated 2026-07-23·Phase 3
Active, not recruiting

Primary endpoint: Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)

InterventionalRandomizedopen762 enrolledStarted 2024-02Completion 2028-0550 sites · United StatesSeagen, a wholly owned subsidiary of Pfizer

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04389632Registry updated 2026-07-06·Phase 1
Recruiting

Primary endpoint: Number of participants with adverse events (AEs)

Interventionalopen1,006 targetStarted 2020-06Completion 2029-0350 sites · United StatesSeagen, a wholly owned subsidiary of Pfizer